DuVall Adam S, Wesevich Austin, Larson Richard A
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, USA.
Curr Hematol Malig Rep. 2023 Dec;18(6):217-225. doi: 10.1007/s11899-023-00706-7. Epub 2023 Jul 25.
Largely, treatment advances in relapsed and/or refractory acute lymphoblastic leukemia (ALL) have been made in B cell disease leaving T cell ALL reliant upon high-intensity chemotherapy. Recent advances in the understanding of the biology of T-ALL and the improvement in immunotherapies have led to new therapeutic pathways to target and exploit. Here, we review the more promising pathways that are able to be targeted and other therapeutic possibilities for T-ALL.
Preclinical models and early-phase clinical trials have shown promising results in some case in the treatment of T-ALL. Targeting many different pathways could lead to the next advancement in the treatment of relapsed and/or refractory disease. Recent advances in cellular therapies have also shown promise in this space. When reviewing the literature as a whole, targeting important pathways and antigens likely will lead to the next advancement in T-ALL survival since intensifying chemotherapy.
在很大程度上，复发和/或难治性急性淋巴细胞白血病（ALL）的治疗进展主要体现在B细胞疾病方面，而T细胞ALL仍依赖高强度化疗。对T-ALL生物学认识的最新进展以及免疫疗法的改进带来了新的可靶向和利用的治疗途径。在此，我们综述T-ALL中更具前景的可靶向途径及其他治疗可能性。
临床前模型和早期临床试验在某些情况下对T-ALL的治疗已显示出有前景的结果。靶向许多不同途径可能会推动复发和/或难治性疾病治疗的进一步发展。细胞疗法的最新进展在这一领域也显示出前景。从整体文献回顾来看，自强化化疗以来，靶向重要途径和抗原可能会推动T-ALL生存率的进一步提高。
